How-to De-Risk Antibody Pair-Based Assay Development

Developing robust, reproducible antibody pair-based immunoassays is critical for guiding drug development, facilitating data-driven decision-making, and projects that continue to future stages. However, assay development is time-consuming, expensive, and complex. Significant time and money is wasted on unreliable solutions, inconsistent conjugation and labeling methods, and disparate validation criteria—all of which impede assay reproducibility and robustness, perpetuating the reproducibility crisis in preclinical studies. Strategies that save time, reduce variability, and optimize assay performance help circumvent these challenges in antibody pair-based immunoassay development, leading to reduced risks and streamlining development.

This guide highlights and breaks down key challenges associated with the development process and offers solutions that support developing, scaling, and delivering reproducible immunoassays. Learn about:

• Why validated, flexible solutions, whether off-the-shelf kits or fully customized reagents, are the key to efficient development.
• Important factors and selection criteria when searching and comparing solutions that minimize risk during development.
• Variables that can impact the reliability and reproducibility of a conjugated antibody over the the course of project.
• Supply chain disruptions and inconsistencies that create assay variability and significant project delays.